Company intelligence / Profile preview

Lubris BioPharma

Weston, Massachusetts, United Stateslubris.net ↗

Ownership: Private
Development stage: Phase 2

Overview

Lubris BioPharma develops and commercializes recombinant human lubricin—a naturally occurring protein that protects tissues from friction-related damage—for the treatment of dry eye disease, osteoarthritis, and other inflammatory or age-related conditions. The company has demonstrated significant clinical improvement in dry eye disease patients. Its lead asset has been outlicensed to a major pharmaceutical partner for ophthalmic indications. Research also explores broader applications such as surgical adhesions and pericarditis.

Therapeutic areas: OtherRheumatologyOphthalmology
Modalities: Recombinant proteins (specifically recombinant human lubricin)
Industry: Biotech

Drug pipeline

1 asset

ECF843

Phase 2

Indications: Dry eye disease

Partnerships

Novartis—outlicensing agreement for ECF843/recombinant human lubricin in ophthalmology/eye diseases.

Beyond the preview

Go deeper on Lubris BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lubris BioPharma.

Explore the full profile